Linda Mileshkin

Pan-cancer analysis of whole genomes

Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse et al. · Nature · 2020 · 3.1K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell et al. · Journal of Clinical Oncology · 2020 · 777 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols et al. · The Lancet Oncology · 2016 · 497 citations

Oncology, Tumor Heterogeneity, Unknown Primary +13